Devonian Health Group Inc Ordinary Shares - New GSD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Devonian Health Group Provides Update on its Planned NYSE American Listing
-
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
-
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
-
Devonian Health Group Anticipates to Commence Trading on the NYSE American
-
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
-
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
Trading Information
- Previous Close Price
- CA$7.50
- Day Range
- CA$7.10–7.10
- 52-Week Range
- CA$5.10–15.00
- Bid/Ask
- CA$6.75 / CA$7.50
- Shares Outstanding
- 2.78M
- Market Cap
- CA$19.74M
- Volume/Avg
- 500 / 2,787
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.groupedevonian.com
Valuation
|
Metric
|
GSD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.22 |
Price/Sales | 7.19 |
Price/Cash Flow | — |
Price/Earnings
GSD
Financial Strength
|
Metric
|
GSD
|
|---|---|
Quick Ratio | 0.78 |
Current Ratio | 1.00 |
Interest Coverage | −718.21 |
Quick Ratio
GSD
Profitability
|
Metric
|
GSD
|
|---|---|
Return on Assets (Normalized) | −32.13% |
Return on Equity (Normalized) | −103.52% |
Return on Invested Capital (Normalized) | −55.17% |
Return on Assets
GSD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^#ZH#h | LOCK|g@pr^ | $127B | |||
| Moderna Inc
MRNA
| LOCK|>%bJsm! | LOCK|PD | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|FlRf$Z | LOCK|$%Zd | $81B | |||
| argenx SE ADR
ARGX
| LOCK|xhtLNz | LOCK|@< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%mMB#Y | LOCK|G@ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$tZt@v> | LOCK|mngx | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pRG$xC> | LOCK|v#XZ% | $27B | |||
| Incyte Corp
INCY
| LOCK|&<@<tv^ | LOCK|k?^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@P<<K%^ | LOCK|cN@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|FrlL?fx | LOCK|x^% | $14B |
United States